AN OPEN-LABEL, PHASE 1A/B STUDY OF AB248, A CD8+ SELECTIVE IL-2 MUTEIN FUSION PROTEIN, ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS

1David R Spigel*, 2Costantine Albany, 3Michael Chisamore, 4Kelly D Moynihan, 4Christopher DeNagro, 5Jennifer Visich, 5Matt Ant, 6Xiaohan Liu, 4Mark Sayles, 4Andrea Pickall, 1Elizabeth I Buchbinder, 1Sarah Cannon Research Institute, Nashville, TN, USA; 2Horizon Oncology and Research Center, Lafayette, IN, USA; 3Merk and Co., Inc., Rahway, NJ, USA; 4Asher Biotherapeutics, Inc., South San Francisco, CA, USA; 5Dana-Farber Cancer Institute, Boston, MA, USA

Background: High-dose interleukin-2 (HD IL-2) induces durable clinical responses in patients with melanoma and RCC, but severe toxicity limits its therapeutic utility. Early clinical data from several not-α IL-2Rbg agonists suggest better tolerability but lower response rates compared to historical HD IL-2.1 2

In patients, these not-α IL-2R agonists demonstrate a NK cell bias, retain activity on Tregs, and exhibit limited CD8+ T cell expansion.3–5

AB248 is a CD8+ T cell-selective IL-2 with over 500-fold preference for CD8+ T cells over other immune cell types. AB248 has demonstrated a differentiated preclinical profile, with compelling anti-tumor activity when given alone and in combination with anti-PD1 in multiple murine models. Preclinical data suggests that AB248 may yield an improved therapeutic index compared to broadly acting IL-2Rbg agonists by increasing CD8+ T cell activation while avoiding NK cell-driven toxicity and Treg-mediated immunosuppression.6 Here we introduce the first-in-human study evaluating AB248 administered alone and in combination with pembrolizumab in subjects with advanced solid tumors who progressed after prior standard-of-care therapies.

Methods: This open-label phase 1a/b study consisting of a dose-escalation and expansion phase aims to investigate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of AB248 alone or in combination with pembrolizumab. Subjects with locally advanced metastatic tumors will be enrolled, including melanoma, RCC, NSCLC, and SCCHN, which progressed on prior therapies (e.g. anti-PD(L)1), and first-line SCCHN during the expansion phase. Key eligibility criteria include age ≥18 years, ECOG ≤1, measurable disease per REGIST v1.1, adequate end-organ function, and no autoimmune disease. The dose-escalation will follow the Bayesian Optimal Interval (BOIN) design and enroll subjects at multiple dose levels and schedules for both monotherapy and combination portions. Backfill cohorts for paired-tumor biopsies are included during dose-escalation. Upon identifying a suitable dose and schedule based on the totality of cumulative data, additional subjects will be enrolled in indication-specific expansion cohorts according to the Simon 2-stage design. The primary objectives for this study are to assess the safety and tolerability of AB248 alone or in combination with pembrolizumab. Secondary objectives include assessing PK, PD, immunogenicity, and anti-tumor activity. Exploratory objectives include evaluating the potential response-predictive and/or associated changes in immune cells, blood, and tissue biomarkers. Tumor assessments will be performed every 6 weeks for the first 30 weeks and every 8–9 weeks thereafter. Adverse events will be assessed by CTCAE v5.0, except CRS, assessed by ASTCT criteria. This study is currently enrolling.

Acknowledgements: We extend our thanks to the patients, their families, and the investigators and their site staff members who are making this trial possible. We would like to acknowledge Trisha Chung and Janice Tran, AsherBio employees, for their contributions to the trial.

Trial Registration: NCT05653882

REFERENCES:

Ethics Approval: This study has been approved by each participating site: Dana Farber Cancer Institute IRB approval #12092022. All participants gave their informed consent before taking part in the study.

http://dx.doi.org/10.1136/jitc-2023-SITC2023.0753